Crispr Therapeutics (NASDAQ:CRSP) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday, November 30th, BidAskClub reports.

A number of other research firms have also recently commented on CRSP. Canaccord Genuity boosted their target price on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research report on Wednesday, November 20th. Wells Fargo & Co reissued a “buy” rating on shares of Crispr Therapeutics in a research report on Tuesday, November 19th. Goldman Sachs Group boosted their target price on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. Oppenheimer upped their price target on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, November 25th. Finally, William Blair raised shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $69.54.

Crispr Therapeutics stock opened at $65.95 on Friday. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $74.00. The firm has a 50 day moving average price of $61.00 and a 200 day moving average price of $49.02. The company has a market cap of $3.61 billion, a price-to-earnings ratio of -19.17 and a beta of 3.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.

Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. Sell-side analysts predict that Crispr Therapeutics will post 0.65 EPS for the current year.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock valued at $3,620,760 over the last three months. 21.40% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the business. Nikko Asset Management Americas Inc. boosted its position in shares of Crispr Therapeutics by 48.4% in the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after acquiring an additional 906,006 shares during the period. ARK Investment Management LLC lifted its position in Crispr Therapeutics by 34.7% in the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after purchasing an additional 701,332 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Crispr Therapeutics by 19.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after purchasing an additional 121,176 shares during the period. Wells Fargo & Company MN lifted its position in Crispr Therapeutics by 23.9% in the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares during the period. Finally, Orbimed Advisors LLC bought a new position in Crispr Therapeutics in the third quarter worth $21,167,000. Institutional investors own 49.82% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

See Also: What is systematic risk?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.




Source link